Loading...
Market
Which major pharmaceutical company will adopt similar treatment strategies by end of 2025?
2
Resolution / Starting Odds
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Press releases from pharmaceutical companies
Story
Lancet Study: New Cervical Cancer Treatment Cuts Death Risk by 40%, Major Breakthrough in 20 Years
Oct 15, 2024, 09:24 AM
A new cervical cancer treatment regime has been identified as a significant advancement in medical care, reportedly reducing the risk of death from the disease by 40%. This breakthrough, described as the most substantial improvement in cervical cancer treatment in two decades, involves a change in the order of drug administration. Researchers highlighted that this simple adjustment has transformed survival rates for patients. The findings were published in a study by The Lancet, marking a pivotal moment in the ongoing fight against cervical cancer.
View original story
Similar markets
Johnson & Johnson • 25%
Merck • 25%
AstraZeneca • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Other • 25%
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Johnson & Johnson • 25%
Eli Lilly • 25%
Both • 25%
Neither • 25%
None • 25%
1-2 companies • 25%
3-5 companies • 25%
More than 5 companies • 25%
Pfizer • 25%
Roche • 25%
GlaxoSmithKline • 25%
Other • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Novo Nordisk • 25%
Sanofi • 25%
Merck • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Johnson & Johnson • 25%
Novartis • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%